The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Meaning I don't care if the Nottingham vaccine that is the scancell vaccine ends up being known as the Merck or Roche etc vaccine :)))
Also scancell are almost certainly in some form of dialogue with potential partners we have discussed CEPI here and how Covidity would fit their recent call and quite possibly scancell have applied... the sudden twitter silence and no more CEPI retweets from RG after a flurry... plus the article mentions.... And I did and still do see CEPI as being a potential great partner however I think it probably if Lindy is confident which seems a yes to get the data first... I have been ok with the idea of giving Covidity at cost as the benefits for scancell would still be huge... now though having seen whats happened to moderna and BioNTech... I reckon yes let's get some 'unrivalled' data in first and take it from there with who ever in industry scancell are in dialogue with...
This article has been posted before here.
https://www.nature.com/articles/s41586-020-2550-z
It is worth reading the whole of the abstract:
"Memory T cells induced by previous pathogens can shape susceptibility to, and the clinical severity of, subsequent infections1. Little is known about the presence in humans of pre-existing memory T cells that have the potential to recognize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we studied T cell responses against the structural (nucleocapsid (N) protein) and non-structural (NSP7 and NSP13 of ORF1) regions of SARS-CoV-2 in individuals convalescing from coronavirus disease 2019 (COVID-19) (n = 36). In all of these individuals, we found CD4 and CD8 T cells that recognized multiple regions of the N protein. Next, we showed that patients (n = 23) who recovered from SARS (the disease associated with SARS-CoV infection) possess long-lasting memory T cells that are reactive to the N protein of SARS-CoV 17 years after the outbreak of SARS in 2003; these T cells displayed robust cross-reactivity to the N protein of SARS-CoV-2. We also detected SARS-CoV-2-specific T cells in individuals with no history of SARS, COVID-19 or contact with individuals who had SARS and/or COVID-19 (n = 37). SARS-CoV-2-specific T cells in uninfected donors exhibited a different pattern of immunodominance, and frequently targeted NSP7 and NSP13 as well as the N protein. Epitope characterization of NSP7-specific T cells showed the recognition of protein fragments that are conserved among animal betacoronaviruses but have low homology to ‘common cold’ human-associated coronaviruses. Thus, infection with betacoronaviruses induces multi-specific and long-lasting T cell immunity against the structural N protein. Understanding how pre-existing N- and ORF1-specific T cells that are present in the general population affect the susceptibility to and pathogenesis of SARS-CoV-2 infection is important for the management of the current COVID-19 pandemic."
Yes, and in addition to targeting epitopes (plural) of the highly conserved N protein, it does suggest that Covid19 could be a goner with this vaccine.
It also has a head start on other Coronaviruses past and present, since up till now the N protein is also conserved across all Coronaviruses.
16 crikey!
I wonder though probably very good reasons why but in theory scancell could put multiple variant S targeting antigens in one vax? a kinda shotgun approach...
Anyway every day a lesson I really did not get why BioNTech was not making an mRNA Covidity I now know....The Lindy way... again if she pulls this off this is her fast track to stardom in the immuno field...
crumbs, if I recall correctly, SCIB2 targets 16 epitopes!
We don't actually know if there is a limit.
https://www.scancell.co.uk/immunobody
https://www.scancell.co.uk/covidity
Very bullish article, thanks bill.
Then just to make is super interesting ... you throw in Avidimab!
Just took a twist for the good to me with that scancell quote about mRNA not being able to contain more than one antigen and our immuoBody of course capable of containing multiple (can't remember off top me ed how many SCIB1 has 4) .....
Now makes sense why no mRNA n targeting vaxs have appeared... you would need a shot of both....
Add that to the other mRNA issues and the advantages of DNA.... again the data has to really back but... we could see a real paradigm shift if scancell pulls this off..... This has already been waved right in front of Sahin too at his own conference... hmmmm ... gonna get super interesting I think